KC-1698

MC38-Trop2-Cell-Line

22639

Home » 细胞系 » MC38-Trop2-Cell-Line

Background of MC38-Trop2-Cell-Line

TROP2 (Trophoblast cell-surface antigen 2), officially named TACSTD2 (Tumor-associated calcium signal transducer 2), is also known as EGP-1, GA733-1, and M1S1. It is a cell surface glycoprotein involved in regulating cancer cell proliferation, migration, and invasion through pathways like MAPK and calcium signaling. TROP2 is minimally expressed in normal tissues but overexpressed in various epithelial cancers, including breast, lung, colorectal, and pancreatic cancers. High TROP2 expression is often associated with poor prognosis and tumor aggressiveness. This has made it a prominent therapeutic target, leading to the FDA-approved antibody-drug conjugate (ADC) Sacituzumab govitecan for breast and urothelial carcinomas, with numerous other TROP2-targeted ADCs in clinical development.

Specifications

Catalog Number	KC-1698
Cell Line Name	MC38-Trop2-Cell-Line
NCBI/UniProt Accession Number	NM_002353.2
Clone Number	2#
Host Cell Line	Mouse MC38 cell line
Description	Stable MC38 cell line expressing exogenous human Trop2 gene
Quantity	Two vials of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% DMEM+20% FBS+10% DMSO
Propagation Medium	DMEM+10%FBS+5µg/mL Puromycin
Selection Marker	Puromycin
Morphology	Epithelial
Subculture	Split the saturated culture at a ratio of 1:4~1:8 every 2~3 days
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 30 hours
Mycoplasma Status	Negative
In Vivo Validation	YES

Cell Line Generation

MC38-Trop2 Cell Line was generated using a lentiviral vector expressing the human Trop2 sequence.

Characterization

Figure 1: Characterization of human Trop2 overexpression in MC38-Trop2 stable clones using FACS.

Figure 2: Tumor growth and body weight changes in C57BL/6J mice bearing MC38-Trop2 tumors(Inoculated with 5×10⁶ tumor cells, n=7)

Cell Resuscitation

Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
Pre-chill the freezing medium on ice and label the cryovials accordingly.
Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Li, Tong et al. “Trop2-Based Antibody-Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy.” Current oncology (Toronto, Ont.) vol. 33,2 92. 3 Feb. 2026, doi:10.3390/curroncol33020092.
2. Rogers, Jane E. “TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors.” Molecular diagnosis & therapy, 10.1007/s40291-026-00835-8. 11 Feb. 2026, doi:10.1007/s40291-026-00835-8.
3. Ye, Mao, and Bita Badehnoosh. “The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor.” Cancer cell international vol. 26,1 123. 6 Feb. 2026, doi:10.1186/s12935-026-04210-9.
4. Moon, Dong Oh. “Structure-guided discovery strategies for Trop2-targeted small molecule inhibitors.” Bulletin du cancer, S0007-4551(26)00054-8. 9 Feb. 2026, doi:10.1016/j.bulcan.2025.11.016.